CN114206893A - (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 - Google Patents
(杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 Download PDFInfo
- Publication number
- CN114206893A CN114206893A CN202080056681.7A CN202080056681A CN114206893A CN 114206893 A CN114206893 A CN 114206893A CN 202080056681 A CN202080056681 A CN 202080056681A CN 114206893 A CN114206893 A CN 114206893A
- Authority
- CN
- China
- Prior art keywords
- pyran
- methyl
- triazol
- thio
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000005842 heteroatom Chemical group 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 244
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 342
- -1 tetrahydro-2H-pyran-4, 4-diyl Chemical group 0.000 claims description 289
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 72
- 125000001424 substituent group Chemical group 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 208000020832 chronic kidney disease Diseases 0.000 claims description 26
- 206010016654 Fibrosis Diseases 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 25
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 24
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 230000004761 fibrosis Effects 0.000 claims description 19
- 208000037765 diseases and disorders Diseases 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- 239000011737 fluorine Substances 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 17
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 14
- 208000022873 Ocular disease Diseases 0.000 claims description 14
- 208000016222 Pancreatic disease Diseases 0.000 claims description 14
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 14
- 208000027866 inflammatory disease Diseases 0.000 claims description 13
- 208000019423 liver disease Diseases 0.000 claims description 13
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 8
- 208000033626 Renal failure acute Diseases 0.000 claims description 8
- 206010052779 Transplant rejections Diseases 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 201000011040 acute kidney failure Diseases 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 208000019693 Lung disease Diseases 0.000 claims description 7
- 210000004556 brain Anatomy 0.000 claims description 7
- 208000004296 neuralgia Diseases 0.000 claims description 7
- 208000024691 pancreas disease Diseases 0.000 claims description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 claims description 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 4
- MYKUIDQPHNNALF-XATIALBVSA-N OC([C@@H](C1=C(C=CC=C1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@@H](C1=C(C=CC=C1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C MYKUIDQPHNNALF-XATIALBVSA-N 0.000 claims description 4
- CVZRNBYTUIGJTN-WTGKAQRQSA-N OC[C@@H](C1=CC=CC=C1)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound OC[C@@H](C1=CC=CC=C1)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO CVZRNBYTUIGJTN-WTGKAQRQSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims description 4
- VCUAXODKLDNVTA-CCUOSZMHSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(1R)-2-hydroxy-2-methyl-1-[2-(2-methylpropyl)phenyl]propyl]sulfanyl-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Chemical compound OC([C@@H](C1=C(C=CC=C1)CC(C)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C VCUAXODKLDNVTA-CCUOSZMHSA-N 0.000 claims description 3
- URNHDQNEVNGJOB-CCUOSZMHSA-N (2S,3R,4S,5R,6R)-2-[(R)-(1-hydroxycyclohexyl)-(2-methylphenyl)methyl]sulfanyl-6-(hydroxymethyl)-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Chemical compound OC1(CCCCC1)[C@H](S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C URNHDQNEVNGJOB-CCUOSZMHSA-N 0.000 claims description 3
- KYJFFRQAMGUMCP-WIBPYNGWSA-N C1(=C(C=CC=C1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=CC=CC=C1 Chemical compound C1(=C(C=CC=C1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=CC=CC=C1 KYJFFRQAMGUMCP-WIBPYNGWSA-N 0.000 claims description 3
- GHGRZEIXQFGNPY-WWJMMCNDSA-N C1(CC1)C1=C(C=CC=C1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound C1(CC1)C1=C(C=CC=C1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO GHGRZEIXQFGNPY-WWJMMCNDSA-N 0.000 claims description 3
- WAOHGZBWWLZECQ-DYRNCQFLSA-N CC=1SC(=C(N=1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C Chemical compound CC=1SC(=C(N=1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C WAOHGZBWWLZECQ-DYRNCQFLSA-N 0.000 claims description 3
- ZVOPHSHOWOEIHG-XATIALBVSA-N FC=1C(=C(C=CC=1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C Chemical compound FC=1C(=C(C=CC=1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C ZVOPHSHOWOEIHG-XATIALBVSA-N 0.000 claims description 3
- PAVDSVBSVHEIBU-HCRCWBKNSA-N OC([C@@H](C1=C(C=CC=C1)CCO)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@@H](C1=C(C=CC=C1)CCO)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C PAVDSVBSVHEIBU-HCRCWBKNSA-N 0.000 claims description 3
- JSMROVHTKDYUEP-CCUOSZMHSA-N OC([C@@H](C1=CC=CC2=CC=CC=C12)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@@H](C1=CC=CC2=CC=CC=C12)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C JSMROVHTKDYUEP-CCUOSZMHSA-N 0.000 claims description 3
- FKLPGGSLYWUHAY-WWJMMCNDSA-N OC1(CCCC1)[C@H](S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C Chemical compound OC1(CCCC1)[C@H](S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C FKLPGGSLYWUHAY-WWJMMCNDSA-N 0.000 claims description 3
- DOEAVJNELYUBKI-PIYILYQRSA-N OC1(CCCCC1)[C@H](S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=NOC=C1C Chemical compound OC1(CCCCC1)[C@H](S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=NOC=C1C DOEAVJNELYUBKI-PIYILYQRSA-N 0.000 claims description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- IHFJDOKDEMDMPK-QKEDNXFGSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(1R)-2-hydroxy-2-methyl-1-(4-methylthiophen-3-yl)propyl]sulfanyl-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Chemical compound OC([C@@H](C1=CSC=C1C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C IHFJDOKDEMDMPK-QKEDNXFGSA-N 0.000 claims description 2
- ZVTTYXUKQGMTDA-TUFAUPKWSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(1R,2S)-2-hydroxy-1-[2-(trifluoromethyl)phenyl]butyl]sulfanyl-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Chemical compound O[C@H]([C@@H](C1=C(C=CC=C1)C(F)(F)F)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)CC ZVTTYXUKQGMTDA-TUFAUPKWSA-N 0.000 claims description 2
- IXFHANIKWLCTHH-DYRNCQFLSA-N (2S,3R,4S,5R,6R)-2-[(1R)-1-(3,5-dimethyl-1,2-oxazol-4-yl)-2-hydroxy-2-methylpropyl]sulfanyl-6-(hydroxymethyl)-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Chemical compound CC1=NOC(=C1[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C IXFHANIKWLCTHH-DYRNCQFLSA-N 0.000 claims description 2
- JJZPDIJDTAPLKD-WWJMMCNDSA-N (2S,3R,4S,5R,6R)-2-[(R)-(1-hydroxy-3,3-dimethylcyclobutyl)-(2-methylphenyl)methyl]sulfanyl-6-(hydroxymethyl)-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Chemical compound OC1(CC(C1)(C)C)[C@H](S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C JJZPDIJDTAPLKD-WWJMMCNDSA-N 0.000 claims description 2
- XYAZFHUFNFFRDL-WTGKAQRQSA-N BrC1=C(C=CC=C1)[C@H](CO)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound BrC1=C(C=CC=C1)[C@H](CO)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO XYAZFHUFNFFRDL-WTGKAQRQSA-N 0.000 claims description 2
- YEQKHJOSZVGPDE-ARQYYYJSSA-N C(C)C([C@@H](C=1C(=NOC=1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(CC)O Chemical compound C(C)C([C@@H](C=1C(=NOC=1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(CC)O YEQKHJOSZVGPDE-ARQYYYJSSA-N 0.000 claims description 2
- DHEABPUFHXGQJB-HCRCWBKNSA-N C(C)C1=C(C=CC=C1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound C(C)C1=C(C=CC=C1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO DHEABPUFHXGQJB-HCRCWBKNSA-N 0.000 claims description 2
- FAVVWDQUIBYZSF-DYRNCQFLSA-N CC=1OC(=C(N=1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C Chemical compound CC=1OC(=C(N=1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C FAVVWDQUIBYZSF-DYRNCQFLSA-N 0.000 claims description 2
- NXIYXHXCPKFIBH-ARQYYYJSSA-N ClC1=C(C=CC=C1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound ClC1=C(C=CC=C1)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO NXIYXHXCPKFIBH-ARQYYYJSSA-N 0.000 claims description 2
- RWNIGAFTMQYPPS-IKADZPNNSA-N ClC1=C(C=CC=C1Cl)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound ClC1=C(C=CC=C1Cl)[C@H](C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO RWNIGAFTMQYPPS-IKADZPNNSA-N 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims description 2
- ZDUNTUNDBSQXQO-MSXPJASTSA-N OC([C@@H](C1=C(C=CC=C1)C(F)(F)F)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC2=CC=CC=C2C=C1)O)CO)(C)C Chemical compound OC([C@@H](C1=C(C=CC=C1)C(F)(F)F)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC2=CC=CC=C2C=C1)O)CO)(C)C ZDUNTUNDBSQXQO-MSXPJASTSA-N 0.000 claims description 2
- RTDBVNIEYVGLJM-WWJMMCNDSA-N OC([C@@H](C1=C(C=CC=C1)CCC)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@@H](C1=C(C=CC=C1)CCC)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C RTDBVNIEYVGLJM-WWJMMCNDSA-N 0.000 claims description 2
- RAXIHXUNDYGLLH-ZPYPPCPKSA-N OC([C@@H](C1=C(C=CC=C1)CCCCC)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@@H](C1=C(C=CC=C1)CCCCC)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C RAXIHXUNDYGLLH-ZPYPPCPKSA-N 0.000 claims description 2
- OEMQPUOZMXHHMQ-ARQYYYJSSA-N OC([C@@H](C=1C(=NC=CC=1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@@H](C=1C(=NC=CC=1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C OEMQPUOZMXHHMQ-ARQYYYJSSA-N 0.000 claims description 2
- OVADRJQRWINEEV-ARQYYYJSSA-N OC([C@@H](C=1C=NC=CC=1C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@@H](C=1C=NC=CC=1C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C OVADRJQRWINEEV-ARQYYYJSSA-N 0.000 claims description 2
- YROIJMNDEZGDSH-WYRSWYAISA-N OC1(CC(C1)C)[C@H](S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C Chemical compound OC1(CC(C1)C)[C@H](S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C YROIJMNDEZGDSH-WYRSWYAISA-N 0.000 claims description 2
- HPPLNBOOFRJQGH-MNQQAKMZSA-N OC1(CCC1)[C@H](CC1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C Chemical compound OC1(CCC1)[C@H](CC1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C HPPLNBOOFRJQGH-MNQQAKMZSA-N 0.000 claims description 2
- GCHUPPIDKVSURV-GUQVHUPFSA-N OC[C@@H](C1=C(C=CC=C1)C(C)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound OC[C@@H](C1=C(C=CC=C1)C(C)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO GCHUPPIDKVSURV-GUQVHUPFSA-N 0.000 claims description 2
- ZVTTYXUKQGMTDA-CVTZZESPSA-N O[C@@H]([C@@H](C1=C(C=CC=C1)C(F)(F)F)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)CC Chemical compound O[C@@H]([C@@H](C1=C(C=CC=C1)C(F)(F)F)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)CC ZVTTYXUKQGMTDA-CVTZZESPSA-N 0.000 claims description 2
- UOWHCAKKYIRMSX-UHFFFAOYSA-N [N].C1CNC1 Chemical compound [N].C1CNC1 UOWHCAKKYIRMSX-UHFFFAOYSA-N 0.000 claims description 2
- IUKQLMGVFMDQDP-UHFFFAOYSA-N azane;piperidine Chemical compound N.C1CCNCC1 IUKQLMGVFMDQDP-UHFFFAOYSA-N 0.000 claims description 2
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 claims 1
- XSDHLCGOYZWTFR-UHFFFAOYSA-N OCC1OCC(C(C1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O Chemical compound OCC1OCC(C(C1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O XSDHLCGOYZWTFR-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010001517 Galectin 3 Proteins 0.000 abstract description 46
- 239000003112 inhibitor Substances 0.000 abstract description 10
- 102000000802 Galectin 3 Human genes 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 description 170
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 153
- 239000000543 intermediate Substances 0.000 description 101
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 98
- 239000011541 reaction mixture Substances 0.000 description 74
- 239000007787 solid Substances 0.000 description 71
- 239000000243 solution Substances 0.000 description 65
- 238000002953 preparative HPLC Methods 0.000 description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- 239000010410 layer Substances 0.000 description 57
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 50
- 239000012044 organic layer Substances 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 44
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 43
- 102100039558 Galectin-3 Human genes 0.000 description 37
- 239000003921 oil Substances 0.000 description 36
- 235000019198 oils Nutrition 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 29
- 239000012267 brine Substances 0.000 description 29
- 230000005764 inhibitory process Effects 0.000 description 29
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 25
- 239000003480 eluent Substances 0.000 description 24
- 238000004128 high performance liquid chromatography Methods 0.000 description 24
- 239000007864 aqueous solution Substances 0.000 description 23
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 22
- 239000013058 crude material Substances 0.000 description 22
- 238000001914 filtration Methods 0.000 description 22
- 238000000746 purification Methods 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 238000001035 drying Methods 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 19
- 125000006239 protecting group Chemical group 0.000 description 19
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 18
- 206010012601 diabetes mellitus Diseases 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 238000001514 detection method Methods 0.000 description 15
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 14
- 238000010828 elution Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 13
- 208000019425 cirrhosis of liver Diseases 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 11
- 102000007563 Galectins Human genes 0.000 description 11
- 108010046569 Galectins Proteins 0.000 description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 11
- 238000011321 prophylaxis Methods 0.000 description 11
- 125000004076 pyridyl group Chemical group 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 11
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 239000007832 Na2SO4 Substances 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 206010019280 Heart failures Diseases 0.000 description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 201000009594 Systemic Scleroderma Diseases 0.000 description 9
- 206010042953 Systemic sclerosis Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 208000005069 pulmonary fibrosis Diseases 0.000 description 9
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 125000000842 isoxazolyl group Chemical group 0.000 description 8
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 7
- 206010018364 Glomerulonephritis Diseases 0.000 description 7
- 150000004702 methyl esters Chemical class 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- TXVVVEUSVBLDED-UHFFFAOYSA-N 1-(bromomethyl)-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1CBr TXVVVEUSVBLDED-UHFFFAOYSA-N 0.000 description 6
- KXZSVYHFYHTNBI-UHFFFAOYSA-N 1h-quinoline-2-thione Chemical compound C1=CC=CC2=NC(S)=CC=C21 KXZSVYHFYHTNBI-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 208000017169 kidney disease Diseases 0.000 description 6
- 125000002971 oxazolyl group Chemical group 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 125000000335 thiazolyl group Chemical group 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- 125000001425 triazolyl group Chemical group 0.000 description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000007882 cirrhosis Effects 0.000 description 5
- 208000033679 diabetic kidney disease Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 239000012286 potassium permanganate Substances 0.000 description 5
- 230000037390 scarring Effects 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- YYAAUTBQSOQTGX-UHFFFAOYSA-N FC(C1=C(CSC2=NC3=CC=CC=C3C=C2)C=CC=C1)(F)F Chemical compound FC(C1=C(CSC2=NC3=CC=CC=C3C=C2)C=CC=C1)(F)F YYAAUTBQSOQTGX-UHFFFAOYSA-N 0.000 description 4
- 206010072877 Intestinal fibrosis Diseases 0.000 description 4
- 235000019502 Orange oil Nutrition 0.000 description 4
- 229930182475 S-glycoside Natural products 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000001117 keloid Anatomy 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000010502 orange oil Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 150000003569 thioglycosides Chemical class 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- BRZLGIOBJYQVAV-UHFFFAOYSA-N CC1=NC(=C(N=C1C)C)CSC1OCCCC1 Chemical compound CC1=NC(=C(N=C1C)C)CSC1OCCCC1 BRZLGIOBJYQVAV-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- CYOUFQZNRBTWNQ-UHFFFAOYSA-N FC1(CC(C1)(O)C(C1=C(C=CC=C1)C(F)(F)F)S)F Chemical compound FC1(CC(C1)(O)C(C1=C(C=CC=C1)C(F)(F)F)S)F CYOUFQZNRBTWNQ-UHFFFAOYSA-N 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 208000002260 Keloid Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- OEJUAWSHVYACLO-UHFFFAOYSA-N O=C1CCN(CC1)C(=O)OC(C(Cl)(Cl)Cl)(C)C Chemical compound O=C1CCN(CC1)C(=O)OC(C(Cl)(Cl)Cl)(C)C OEJUAWSHVYACLO-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000009787 cardiac fibrosis Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- HYBCDSDGTPUCMQ-LLVKDONJSA-N ethyl (2R)-2-(dimethylcarbamothioylsulfanyl)-2-phenylacetate Chemical compound CN(C(=S)S[C@@H](C(=O)OCC)C1=CC=CC=C1)C HYBCDSDGTPUCMQ-LLVKDONJSA-N 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000006334 interstitial nephritis Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- NTMHWRHEGDRTPD-UHFFFAOYSA-N n-(4-azidosulfonylphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(S(=O)(=O)N=[N+]=[N-])C=C1 NTMHWRHEGDRTPD-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- NFLSYCABOYZAMW-UHFFFAOYSA-N s-(oxan-2-yl) ethanethioate Chemical compound CC(=O)SC1CCCCO1 NFLSYCABOYZAMW-UHFFFAOYSA-N 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OOHIPDLPISIYKN-JOCHJYFZSA-N (1,1,1-trichloro-2-methylpropan-2-yl) 4-hydroxy-4-[(R)-quinolin-2-ylsulfanyl-[2-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate Chemical compound OC1(CCN(CC1)C(=O)OC(C(Cl)(Cl)Cl)(C)C)[C@@H](C1=C(C=CC=C1)C(F)(F)F)SC1=NC2=CC=CC=C2C=C1 OOHIPDLPISIYKN-JOCHJYFZSA-N 0.000 description 2
- PWSRRKRPSCYOKC-CYBMUJFWSA-N (1,1,1-trichloro-2-methylpropan-2-yl) 4-hydroxy-4-[(R)-sulfanyl-[2-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylate Chemical compound OC1(CCN(CC1)C(=O)OC(C(Cl)(Cl)Cl)(C)C)[C@@H](C1=C(C=CC=C1)C(F)(F)F)S PWSRRKRPSCYOKC-CYBMUJFWSA-N 0.000 description 2
- QZRDHEFNEPDVOO-CHUNWDLHSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-5-methoxy-6-methylsulfanyl-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxan-3-ol Chemical compound OC[C@H]1O[C@H]([C@@H]([C@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)OC)SC QZRDHEFNEPDVOO-CHUNWDLHSA-N 0.000 description 2
- XUNFMWZPSLEDHJ-NZNQWUEYSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-methylsulfanyl-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Chemical compound OC[C@H]1O[C@H]([C@@H]([C@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)SC XUNFMWZPSLEDHJ-NZNQWUEYSA-N 0.000 description 2
- AOLXADMIUZJXSN-CLFJVBSWSA-N (2S,3R,4S,5R,6R)-4-azido-2-[(4,4-difluoro-1-hydroxycyclohexyl)-(3-methylpyridin-2-yl)methyl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol Chemical compound N(=[N+]=[N-])[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)SC(C1=NC=CC=C1C)C1(CCC(CC1)(F)F)O)O AOLXADMIUZJXSN-CLFJVBSWSA-N 0.000 description 2
- NKWPBDOGGJDHOD-UHFFFAOYSA-N 2,2,2-trichloroethyl piperidine-1-carboxylate Chemical compound ClC(Cl)(Cl)COC(=O)N1CCCCC1 NKWPBDOGGJDHOD-UHFFFAOYSA-N 0.000 description 2
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 2
- PPOWHBFTXPMELN-UHFFFAOYSA-N 2-methyl-1-sulfanyl-1-[2-(trifluoromethyl)phenyl]propan-2-ol Chemical compound SC(C(C)(O)C)C1=C(C=CC=C1)C(F)(F)F PPOWHBFTXPMELN-UHFFFAOYSA-N 0.000 description 2
- DOVLQPYYSCACJX-UHFFFAOYSA-N 3,3-difluorocyclobutan-1-one Chemical compound FC1(F)CC(=O)C1 DOVLQPYYSCACJX-UHFFFAOYSA-N 0.000 description 2
- YPBVPJBVLWXKLN-UHFFFAOYSA-N 3-(bromomethyl)-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=NC=CC=C1CBr YPBVPJBVLWXKLN-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- BZXWRVPVZZZAKB-UHFFFAOYSA-N 5-ethynyl-1,2,3-trifluorobenzene Chemical group FC1=CC(C#C)=CC(F)=C1F BZXWRVPVZZZAKB-UHFFFAOYSA-N 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 2
- 208000024985 Alport syndrome Diseases 0.000 description 2
- 206010001889 Alveolitis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- YDZIPYONNZIJHJ-UHFFFAOYSA-N BrC1=C(C=CC=C1)C(C(=O)OCC)=[N+]=[N-] Chemical compound BrC1=C(C=CC=C1)C(C(=O)OCC)=[N+]=[N-] YDZIPYONNZIJHJ-UHFFFAOYSA-N 0.000 description 2
- YPSRDSZDAGEVQP-YENDSXDJSA-N BrC1=C(C=CC=C1)C(CO)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=CC=C1)F)O)CO Chemical compound BrC1=C(C=CC=C1)C(CO)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=CC=C1)F)O)CO YPSRDSZDAGEVQP-YENDSXDJSA-N 0.000 description 2
- VKAQSANHDTWELN-QGZVFWFLSA-N CC([C@@H](C=1C(=NC=CC=1)C(F)(F)F)SC1=NC2=CC=CC=C2C=C1)(C)O Chemical compound CC([C@@H](C=1C(=NC=CC=1)C(F)(F)F)SC1=NC2=CC=CC=C2C=C1)(C)O VKAQSANHDTWELN-QGZVFWFLSA-N 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000608757 Homo sapiens Galectin-3 Proteins 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023421 Kidney fibrosis Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- MYKUIDQPHNNALF-PCVYKCHKSA-N OC(C(C1=C(C=CC=C1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC(C(C1=C(C=CC=C1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C MYKUIDQPHNNALF-PCVYKCHKSA-N 0.000 description 2
- DCVSXLYUTSYAOQ-WWJMMCNDSA-N OC([C@@H](C1=C(C=CC=C1)C(C)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@@H](C1=C(C=CC=C1)C(C)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C DCVSXLYUTSYAOQ-WWJMMCNDSA-N 0.000 description 2
- GCHUPPIDKVSURV-CDRLGBIPSA-N OCC(C1=C(C=CC=C1)C(C)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound OCC(C1=C(C=CC=C1)C(C)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO GCHUPPIDKVSURV-CDRLGBIPSA-N 0.000 description 2
- MWQPPBAGYPLFPF-MFFRZBKQSA-N OC[C@H]1O[C@H]([C@@H]([C@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)SC(C1=C(C=CC=C1)C(F)(F)F)C1(CCNCC1)O Chemical compound OC[C@H]1O[C@H]([C@@H]([C@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)SC(C1=C(C=CC=C1)C(F)(F)F)C1(CCNCC1)O MWQPPBAGYPLFPF-MFFRZBKQSA-N 0.000 description 2
- IMHSXZCRTIGSBE-YFWNVBJASA-N OC[C@H]1O[C@H]([C@@H]([C@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)SC(COC)C1=CC=CC=C1 Chemical compound OC[C@H]1O[C@H]([C@@H]([C@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)SC(COC)C1=CC=CC=C1 IMHSXZCRTIGSBE-YFWNVBJASA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- DFFQUVDTXIVORG-MRVPVSSYSA-N S[C@@H](C(C)(O)C)C=1C(=NC=CC=1)C(F)(F)F Chemical compound S[C@@H](C(C)(O)C)C=1C(=NC=CC=1)C(F)(F)F DFFQUVDTXIVORG-MRVPVSSYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010050207 Skin fibrosis Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 239000005870 Ziram Substances 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical group NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 150000003997 cyclic ketones Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 208000003215 hereditary nephritis Diseases 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- DBBRJAWSDTYYBM-UHFFFAOYSA-N isocyanatocyclopropane Chemical compound O=C=NC1CC1 DBBRJAWSDTYYBM-UHFFFAOYSA-N 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229910052760 oxygen Chemical group 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Substances OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 208000030613 peripheral artery disease Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000001238 wet grinding Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- DUBNHZYBDBBJHD-UHFFFAOYSA-L ziram Chemical compound [Zn+2].CN(C)C([S-])=S.CN(C)C([S-])=S DUBNHZYBDBBJHD-UHFFFAOYSA-L 0.000 description 2
- GMELMFSDPDSXOZ-UHFFFAOYSA-N (1,1,1-trichloro-2-methylpropan-2-yl) carbonochloridate Chemical compound ClC(Cl)(Cl)C(C)(C)OC(Cl)=O GMELMFSDPDSXOZ-UHFFFAOYSA-N 0.000 description 1
- DIXJXZFTHSBZMM-UHFFFAOYSA-N (1,1,1-trichloro-2-methylpropan-2-yl) piperidine-1-carboxylate Chemical compound ClC(C(C)(C)OC(=O)N1CCCCC1)(Cl)Cl DIXJXZFTHSBZMM-UHFFFAOYSA-N 0.000 description 1
- SQQXWIORNCMVFC-QAZYLWTASA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(4-hydroxy-1-methylpiperidin-4-yl)-(2-methylphenyl)methyl]sulfanyl-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Chemical compound OC1(CCN(CC1)C)C(S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C SQQXWIORNCMVFC-QAZYLWTASA-N 0.000 description 1
- SQQXWIORNCMVFC-CCUOSZMHSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(R)-(4-hydroxy-1-methylpiperidin-4-yl)-(2-methylphenyl)methyl]sulfanyl-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol Chemical compound OC1(CCN(CC1)C)[C@H](S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)C1=C(C=CC=C1)C SQQXWIORNCMVFC-CCUOSZMHSA-N 0.000 description 1
- RQBCKNGCMZQWDJ-QMMMGPOBSA-N (2r)-2-phenyl-2-sulfanylethanol Chemical compound OC[C@H](S)C1=CC=CC=C1 RQBCKNGCMZQWDJ-QMMMGPOBSA-N 0.000 description 1
- KEJGAYKWRDILTF-JDDHQFAOSA-N (3ar,5s,6s,6ar)-5-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-ol Chemical compound O1C(C)(C)OC[C@@H]1[C@@H]1[C@H](O)[C@H]2OC(C)(C)O[C@H]2O1 KEJGAYKWRDILTF-JDDHQFAOSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- 125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 description 1
- WGVYCXYGPNNUQA-UHFFFAOYSA-N 1-(bromomethyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1CBr WGVYCXYGPNNUQA-UHFFFAOYSA-N 0.000 description 1
- IQKOWJUUQAATOR-XNJHUCFUSA-N 1-[(4aR,6S,7R,8S,8aR)-7-methoxy-2,2-dimethyl-6-methylsulfanyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-8-yl]-4-(3,4,5-trifluorophenyl)triazole Chemical compound CO[C@@H]1[C@H]([C@H]2OC(OC[C@H]2O[C@H]1SC)(C)C)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F IQKOWJUUQAATOR-XNJHUCFUSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- JZUMPNUYDJBTNO-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 JZUMPNUYDJBTNO-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- YBNMJUAXERDNRJ-UHFFFAOYSA-N 2-(2-bromophenyl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1Br YBNMJUAXERDNRJ-UHFFFAOYSA-N 0.000 description 1
- HOPVUIZLMIEGMJ-UHFFFAOYSA-N 2-(bromomethyl)-3,5,6-trimethylpyrazine Chemical compound CC1=NC(C)=C(CBr)N=C1C HOPVUIZLMIEGMJ-UHFFFAOYSA-N 0.000 description 1
- XGEGMUFLOUPCSL-UHFFFAOYSA-N 2-(bromomethyl)-3-methylpyridine Chemical compound CC1=CC=CN=C1CBr XGEGMUFLOUPCSL-UHFFFAOYSA-N 0.000 description 1
- MAYLZBMEJMCYHL-UHFFFAOYSA-N 2-[(2-methylphenyl)methylsulfanyl]quinoline Chemical compound CC1=CC=CC=C1CSC1=CC=C(C=CC=C2)C2=N1 MAYLZBMEJMCYHL-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- KMJOANZKMSCULR-UHFFFAOYSA-N 2-methoxy-1-phenylethanethiol Chemical compound COCC(S)C1=CC=CC=C1 KMJOANZKMSCULR-UHFFFAOYSA-N 0.000 description 1
- GAYWRLYTWOAYSI-UHFFFAOYSA-N 2-methyl-1-(2-methylphenyl)-1-sulfanylpropan-2-ol Chemical compound SC(C(C)(O)C)C1=C(C=CC=C1)C GAYWRLYTWOAYSI-UHFFFAOYSA-N 0.000 description 1
- GHJGKUKNRIYXKL-UHFFFAOYSA-N 2-methyl-1-phenyl-1-quinolin-2-ylsulfanylpropan-2-ol Chemical compound C=1C=C2C=CC=CC2=NC=1SC(C(C)(O)C)C1=CC=CC=C1 GHJGKUKNRIYXKL-UHFFFAOYSA-N 0.000 description 1
- GXMIUQCGLBGCAY-UHFFFAOYSA-N 2-methyl-1-phenyl-1-sulfanylpropan-2-ol Chemical compound CC(C)(O)C(S)C1=CC=CC=C1 GXMIUQCGLBGCAY-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- HQFLTUZKIRYQSP-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-6-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2N(CC)CSC2=C1 HQFLTUZKIRYQSP-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 1
- FLCLKJQSYHBTIP-UHFFFAOYSA-N 4-[quinolin-2-ylsulfanyl-[2-(trifluoromethyl)phenyl]methyl]piperidin-4-ol Chemical compound OC1(CCNCC1)C(C1=C(C(F)(F)F)C=CC=C1)SC1=NC2=CC=CC=C2C=C1 FLCLKJQSYHBTIP-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- XFPAOXIWRDDQGG-UHFFFAOYSA-N 4-ethynyl-1,2-difluorobenzene Chemical compound FC1=CC=C(C#C)C=C1F XFPAOXIWRDDQGG-UHFFFAOYSA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 206010002889 Aortic aneurysms and dissections Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010054793 Arterial fibrosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005042 Bladder fibrosis Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
- DHEABPUFHXGQJB-MFFRZBKQSA-N C(C)C1=C(C=CC=C1)C(C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound C(C)C1=C(C=CC=C1)C(C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO DHEABPUFHXGQJB-MFFRZBKQSA-N 0.000 description 1
- GHGRZEIXQFGNPY-BJHKXESGSA-N C1(CC1)C1=C(C=CC=C1)C(C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO Chemical compound C1(CC1)C1=C(C=CC=C1)C(C(C)(C)O)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO GHGRZEIXQFGNPY-BJHKXESGSA-N 0.000 description 1
- GGRHIVHIURADPX-UHFFFAOYSA-N CC(C(C1=C(C=CC=C1)C)SC1=NC2=CC=CC=C2C=C1)(C)O Chemical compound CC(C(C1=C(C=CC=C1)C)SC1=NC2=CC=CC=C2C=C1)(C)O GGRHIVHIURADPX-UHFFFAOYSA-N 0.000 description 1
- VKAQSANHDTWELN-UHFFFAOYSA-N CC(C(C=1C(=NC=CC=1)C(F)(F)F)SC1=NC2=CC=CC=C2C=C1)(C)O Chemical compound CC(C(C=1C(=NC=CC=1)C(F)(F)F)SC1=NC2=CC=CC=C2C=C1)(C)O VKAQSANHDTWELN-UHFFFAOYSA-N 0.000 description 1
- PYLXYYJMCFRPRT-MNLARUNXSA-N CC1(OC[C@@H]2[C@H](O1)[C@@H]([C@H]([C@@H](O2)SC)O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)C Chemical compound CC1(OC[C@@H]2[C@H](O1)[C@@H]([C@H]([C@@H](O2)SC)O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)C PYLXYYJMCFRPRT-MNLARUNXSA-N 0.000 description 1
- FLGBRMAZIYXVBV-UHFFFAOYSA-N CN1CCC(CC1)(O)C(C1=NC(=C(N=C1C)C)C)SC1OCCCC1 Chemical compound CN1CCC(CC1)(O)C(C1=NC(=C(N=C1C)C)C)SC1OCCCC1 FLGBRMAZIYXVBV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- XUDCFCUAJZTLJL-UHFFFAOYSA-N ClC1=C(C(=NC=C1)C(C1(CCC(CC1)(F)F)O)S)C Chemical compound ClC1=C(C(=NC=C1)C(C1(CCC(CC1)(F)F)O)S)C XUDCFCUAJZTLJL-UHFFFAOYSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- AVVWPBAENSWJCB-YIDFTEPTSA-N D-gulofuranose Chemical compound OC[C@@H](O)[C@@H]1OC(O)[C@H](O)[C@@H]1O AVVWPBAENSWJCB-YIDFTEPTSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- ZBGTVDSRPIQUKQ-UHFFFAOYSA-N FC1(CC(C1)(O)C(C1=C(C=CC=C1)C(F)(F)F)SC1=NC2=CC=CC=C2C=C1)F Chemical compound FC1(CC(C1)(O)C(C1=C(C=CC=C1)C(F)(F)F)SC1=NC2=CC=CC=C2C=C1)F ZBGTVDSRPIQUKQ-UHFFFAOYSA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100025614 Galectin-related protein Human genes 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001042451 Homo sapiens Galectin-1 Proteins 0.000 description 1
- 101001004750 Homo sapiens Galectin-related protein Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- DXDCAOPZRZBUEF-NIFOPYEASA-N N(=[N+]=[N-])[C@@H]1[C@H]([C@@H](O[C@H]2[C@@H]1OC(OC2)(C)C)SC(C1=NC=CC=C1C)C1(CCC(CC1)(F)F)O)O Chemical compound N(=[N+]=[N-])[C@@H]1[C@H]([C@@H](O[C@H]2[C@@H]1OC(OC2)(C)C)SC(C1=NC=CC=C1C)C1(CCC(CC1)(F)F)O)O DXDCAOPZRZBUEF-NIFOPYEASA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- PRNBTYXNGNXQTB-UHFFFAOYSA-N O=C1CN(C1)C(=O)OC(C(Cl)(Cl)Cl)(C)C Chemical compound O=C1CN(C1)C(=O)OC(C(Cl)(Cl)Cl)(C)C PRNBTYXNGNXQTB-UHFFFAOYSA-N 0.000 description 1
- DCVSXLYUTSYAOQ-BJHKXESGSA-N OC(C(C1=C(C=CC=C1)C(C)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC(C(C1=C(C=CC=C1)C(C)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C DCVSXLYUTSYAOQ-BJHKXESGSA-N 0.000 description 1
- ZVTTYXUKQGMTDA-ZWAZJMGPSA-N OC(C(C1=C(C=CC=C1)C(F)(F)F)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)CC Chemical compound OC(C(C1=C(C=CC=C1)C(F)(F)F)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)CC ZVTTYXUKQGMTDA-ZWAZJMGPSA-N 0.000 description 1
- RTDBVNIEYVGLJM-BJHKXESGSA-N OC(C(C1=C(C=CC=C1)CCC)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC(C(C1=C(C=CC=C1)CCC)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C RTDBVNIEYVGLJM-BJHKXESGSA-N 0.000 description 1
- OEMQPUOZMXHHMQ-DQUCWBKNSA-N OC(C(C=1C(=NC=CC=1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC(C(C=1C(=NC=CC=1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C OEMQPUOZMXHHMQ-DQUCWBKNSA-N 0.000 description 1
- VJEQHAFPJKBDOK-UHFFFAOYSA-N OC(CC1)(CCN1C(O)=O)C(C1=CC=CC=C1)S Chemical compound OC(CC1)(CCN1C(O)=O)C(C1=CC=CC=C1)S VJEQHAFPJKBDOK-UHFFFAOYSA-N 0.000 description 1
- YFYAFCZQHGJKFI-GZBSGOROSA-N OC([C@@H](C1=NOC=C1C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@@H](C1=NOC=C1C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C YFYAFCZQHGJKFI-GZBSGOROSA-N 0.000 description 1
- MYKUIDQPHNNALF-QJKCBQBNSA-N OC([C@H](C1=C(C=CC=C1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C Chemical compound OC([C@H](C1=C(C=CC=C1)C)S[C@@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)O)CO)(C)C MYKUIDQPHNNALF-QJKCBQBNSA-N 0.000 description 1
- OOHIPDLPISIYKN-UHFFFAOYSA-N OC1(CCN(CC1)C(=O)OC(C(Cl)(Cl)Cl)(C)C)C(C1=C(C=CC=C1)C(F)(F)F)SC1=NC2=CC=CC=C2C=C1 Chemical compound OC1(CCN(CC1)C(=O)OC(C(Cl)(Cl)Cl)(C)C)C(C1=C(C=CC=C1)C(F)(F)F)SC1=NC2=CC=CC=C2C=C1 OOHIPDLPISIYKN-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 1
- 108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- 206010035600 Pleural fibrosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- DREFPIQFSWMLFB-UHFFFAOYSA-N SC(C1(CCN(CC1)C)O)C1=NC(=C(N=C1C)C)C Chemical compound SC(C1(CCN(CC1)C)O)C1=NC(=C(N=C1C)C)C DREFPIQFSWMLFB-UHFFFAOYSA-N 0.000 description 1
- DFFQUVDTXIVORG-QMMMGPOBSA-N S[C@H](C(C)(O)C)C=1C(=NC=CC=1)C(F)(F)F Chemical compound S[C@H](C(C)(O)C)C=1C(=NC=CC=1)C(F)(F)F DFFQUVDTXIVORG-QMMMGPOBSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QFIRONPERRUJAN-UHFFFAOYSA-N [NH2-].[Na+].C[Si](N[Si](C)(C)C)(C)C Chemical compound [NH2-].[Na+].C[Si](N[Si](C)(C)C)(C)C QFIRONPERRUJAN-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 108010044715 asialofetuin Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 230000007881 chronic fibrosis Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 238000011220 combination immunotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MZGNSEAPZQGJRB-UHFFFAOYSA-N dimethyldithiocarbamic acid Chemical compound CN(C)C(S)=S MZGNSEAPZQGJRB-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- SCABWMJQWXPFJD-UHFFFAOYSA-N ethyl 2-(2-bromophenyl)-2-hydroxyacetate Chemical compound CCOC(=O)C(O)C1=CC=CC=C1Br SCABWMJQWXPFJD-UHFFFAOYSA-N 0.000 description 1
- MZQXAVZPEZUJIJ-UHFFFAOYSA-N ethyl 2-(2-bromophenyl)acetate Chemical compound CCOC(=O)CC1=CC=CC=C1Br MZQXAVZPEZUJIJ-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000012912 hepatic vascular disease Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Substances [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- AMVCFIFDMKEIRE-UHFFFAOYSA-N methyl 2-(2-bromophenyl)acetate Chemical compound COC(=O)CC1=CC=CC=C1Br AMVCFIFDMKEIRE-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- FGNGTWFJQFTFGN-UHFFFAOYSA-N n,n,n',n'-tetramethylethane-1,2-diamine Chemical compound CN(C)CCN(C)C.CN(C)CCN(C)C FGNGTWFJQFTFGN-UHFFFAOYSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- UJJUEJRWNWVHCM-UHFFFAOYSA-N n-methylsulfamoyl chloride Chemical compound CNS(Cl)(=O)=O UJJUEJRWNWVHCM-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 201000002674 obstructive nephropathy Diseases 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000003408 phase transfer catalysis Methods 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- GJQNVZVOTKFLIU-UHFFFAOYSA-N piperidin-1-ium-4-one;chloride Chemical compound Cl.O=C1CCNCC1 GJQNVZVOTKFLIU-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- RVEZZJVBDQCTEF-UHFFFAOYSA-N sulfenic acid Chemical compound SO RVEZZJVBDQCTEF-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- UBZYKBZMAMTNKW-UHFFFAOYSA-J titanium tetrabromide Chemical compound Br[Ti](Br)(Br)Br UBZYKBZMAMTNKW-UHFFFAOYSA-J 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- JDYCDPFQWXHUDL-UHFFFAOYSA-N trimethyl(methylsulfanyl)silane Chemical compound CS[Si](C)(C)C JDYCDPFQWXHUDL-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019071416 | 2019-08-09 | ||
| EPPCT/EP2019/071416 | 2019-08-09 | ||
| PCT/EP2020/072238 WO2021028336A1 (en) | 2019-08-09 | 2020-08-07 | (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114206893A true CN114206893A (zh) | 2022-03-18 |
Family
ID=71948599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080056681.7A Pending CN114206893A (zh) | 2019-08-09 | 2020-08-07 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12404295B2 (https=) |
| EP (1) | EP4010076B1 (https=) |
| JP (1) | JP7612662B2 (https=) |
| KR (1) | KR102854071B1 (https=) |
| CN (1) | CN114206893A (https=) |
| CA (1) | CA3147082A1 (https=) |
| ES (1) | ES2972509T3 (https=) |
| TW (1) | TWI873165B (https=) |
| WO (1) | WO2021028336A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| US12312362B2 (en) | 2020-10-06 | 2025-05-27 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of Alpha-D-galactopyranosides |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| CN116806219A (zh) | 2021-02-09 | 2023-09-26 | 爱杜西亚药品有限公司 | 羟基杂环烷-氨甲酰基衍生物 |
| RS67032B1 (sr) | 2021-03-03 | 2025-08-29 | Idorsia Pharmaceuticals Ltd | Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom |
| WO2022189459A2 (en) * | 2021-03-10 | 2022-09-15 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| DK2906227T3 (en) | 2012-10-10 | 2018-12-10 | Galectin Therapeutics Inc | GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy |
| CN104755088A (zh) | 2012-10-31 | 2015-07-01 | 格莱克特生物技术公司 | 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) * | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| PL3456717T3 (pl) | 2015-07-06 | 2021-10-25 | Gilead Sciences, Inc. | Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej |
| MX394409B (es) * | 2016-03-04 | 2025-03-24 | Galectin Sciences Llc | Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos. |
| CA3025867A1 (en) * | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| EP3621973A4 (en) | 2017-05-12 | 2021-10-27 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF |
| KR20200015528A (ko) | 2017-05-12 | 2020-02-12 | 갈랙틴 사이언시즈, 엘엘씨 | 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도 |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| CA3080128A1 (en) | 2017-10-31 | 2019-05-09 | Galectin Sciences, Llc | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| JP2022508720A (ja) | 2018-10-15 | 2022-01-19 | ガレクト バイオテック エービー | ガレクチンのガラクトシド阻害剤 |
| CN113286632A (zh) | 2018-10-15 | 2021-08-20 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂前药 |
| WO2020104335A1 (en) | 2018-11-21 | 2020-05-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| WO2021004940A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| US12312362B2 (en) | 2020-10-06 | 2025-05-27 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of Alpha-D-galactopyranosides |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| CN116806219A (zh) | 2021-02-09 | 2023-09-26 | 爱杜西亚药品有限公司 | 羟基杂环烷-氨甲酰基衍生物 |
| RS67032B1 (sr) | 2021-03-03 | 2025-08-29 | Idorsia Pharmaceuticals Ltd | Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom |
-
2020
- 2020-08-07 CN CN202080056681.7A patent/CN114206893A/zh active Pending
- 2020-08-07 CA CA3147082A patent/CA3147082A1/en active Pending
- 2020-08-07 TW TW109126972A patent/TWI873165B/zh active
- 2020-08-07 EP EP20751158.5A patent/EP4010076B1/en active Active
- 2020-08-07 JP JP2022507725A patent/JP7612662B2/ja active Active
- 2020-08-07 ES ES20751158T patent/ES2972509T3/es active Active
- 2020-08-07 WO PCT/EP2020/072238 patent/WO2021028336A1/en not_active Ceased
- 2020-08-07 US US17/633,895 patent/US12404295B2/en active Active
- 2020-08-07 KR KR1020227007509A patent/KR102854071B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4010076C0 (en) | 2024-01-17 |
| WO2021028336A1 (en) | 2021-02-18 |
| ES2972509T3 (es) | 2024-06-13 |
| TW202120102A (zh) | 2021-06-01 |
| JP7612662B2 (ja) | 2025-01-14 |
| KR102854071B1 (ko) | 2025-09-02 |
| EP4010076A1 (en) | 2022-06-15 |
| KR20220044785A (ko) | 2022-04-11 |
| EP4010076B1 (en) | 2024-01-17 |
| TWI873165B (zh) | 2025-02-21 |
| JP2022543666A (ja) | 2022-10-13 |
| US20220315619A1 (en) | 2022-10-06 |
| US12404295B2 (en) | 2025-09-02 |
| CA3147082A1 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114206893A (zh) | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 | |
| TWI864071B (zh) | 2-羥環烷-1-胺甲醯基衍生物 | |
| JP7612663B2 (ja) | （２－アセタミジル）チオ－ベータ－ｄ－ガラクトピラノシド誘導体 | |
| US12291520B2 (en) | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| KR20230145111A (ko) | 히드록시헤테로시클로알칸-카르바모일 유도체 | |
| KR20230083301A (ko) | 알파-d-갈락토피라노사이드의 스피로 유도체 | |
| EA048291B1 (ru) | 2-гидроксициклоалкан-1-карбамоильные производные | |
| CN116745282A (zh) | 抑制2-羟环烷-1-氨甲酰基衍生物的半乳糖凝集素-3 | |
| EA050798B1 (ru) | 2-гидроксициклоалкан-1-карбамоильные производные, ингибирующие галектин-3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |